Journal of Clinical Oncology, Vol 10, 1666-1673, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer

MA Smith, PC Adamson, FM Balis, J Feusner, L Aronson, RF Murphy, ME Horowitz, G Reaman, GD Hammond and RM Fenton
Pediatric Branch, National Cancer Institute, Bethesda, MD 20892.

PURPOSE: Recent reports of the dramatic antitumor effect of all-trans- retinoic acid (RA) in patients with acute promyelocytic leukemia (APL) have renewed interest in the oncologic indications for retinoids. Furthermore, a variety of pediatric tumors are responsive to RA in vitro, which provides additional rationale for a phase I evaluation of RA in children with cancer that is refractory to standard therapy. PATIENTS AND METHODS: A phase I trial of RA administered orally twice daily for 28-day treatment courses was performed. Cohorts of at least three pediatric cancer patients were entered at successive RA dose levels (from 45 to 80 mg/m2/d) until dose-limiting toxicity (DLT) was consistently observed. RESULTS: The maximum-tolerated dose (MTD) of RA was 60 mg/m2/d. Three of eight patients at the 80-mg/m2/d dose level developed reversible pseudotumor cerebri that necessitated discontinuation of the agent. Both patients with APL achieved complete remission (CR), whereas no patients with solid tumors had objective responses. Pharmacokinetic studies demonstrated a relatively short terminal half-life for RA (45 minutes), with diminution in plasma levels after chronic dosing. CONCLUSIONS: The MTD and recommended phase II dose for RA in children is 60 mg/m2/d given twice daily. Reversible CNS toxicity related to RA-induced pseudotumor cerebri is dose- limiting. Two children with APL achieved a CR to RA, which supports the inclusion of pediatric patients in clinical trials that evaluate the use of RA for patients with APL.

This article has been cited by other articles:

				J. R. Muindi, M. D. Roth, R. A. Wise, J. E. Connett, G. T. O'Connor, J. W. Ramsdell, N. W. Schluger, M. Romkes, R. A. Branch, F. C. Sciurba, et al. Pharmacokinetics and Metabolism of All-trans- and 13-cis-Retinoic Acid in Pulmonary Emphysema Patients J. Clin. Pharmacol., January 1, 2008; 48(1): 96 - 107. [Abstract] [Full Text] [PDF]

				G. J.L. Kaspers and C. M. Zwaan Pediatric acute myeloid leukemia: towards high-quality cure of all patients Haematologica, November 1, 2007; 92(11): 1519 - 1532. [Abstract] [Full Text] [PDF]

				C. J. Cifelli and A. C. Ross Chronic Vitamin A Status and Acute Repletion with Retinyl Palmitate Are Determinants of the Distribution and Catabolism of all-trans-Retinoic Acid in Rats J. Nutr., January 1, 2007; 137(1): 63 - 70. [Abstract] [Full Text] [PDF]

				C. J. Cifelli and A. C. Ross All-trans-retinoic acid distribution and metabolism in vitamin A-marginal rats. Am J Physiol Gastrointest Liver Physiol, August 1, 2006; 291(2): G195 - G202. [Abstract] [Full Text] [PDF]

				J. G. Villablanca, M. D. Krailo, M. M. Ames, J. M. Reid, G. H. Reaman, and C. P. Reynolds Phase I Trial of Oral Fenretinide in Children With High-Risk Solid Tumors: A Report From the Children's Oncology Group (CCG 09709) J. Clin. Oncol., July 20, 2006; 24(21): 3423 - 3430. [Abstract] [Full Text] [PDF]

				D. P. Lee, J. M. Skolnik, and P. C. Adamson Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency J. Clin. Oncol., November 20, 2005; 23(33): 8431 - 8441. [Abstract] [Full Text] [PDF]

				A. M. Testi, A. Biondi, F. L. Coco, M. L. Moleti, F. Giona, M. Vignetti, G. Menna, F. Locatelli, A. Pession, E. Barisone, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children Blood, July 15, 2005; 106(2): 447 - 453. [Abstract] [Full Text] [PDF]

				S. de Botton, V. Coiteux, S. Chevret, C. Rayon, E. Vilmer, M. Sanz, J. de La Serna, N. Philippe, A. Baruchel, G. Leverger, et al. Outcome of Childhood Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid and Chemotherapy J. Clin. Oncol., April 15, 2004; 22(8): 1404 - 1412. [Abstract] [Full Text] [PDF]

				A. Garaventa, R. Luksch, M. S. L. Piccolo, E. Cavadini, P. G. Montaldo, M. R. Pizzitola, L. Boni, M. Ponzoni, A. Decensi, B. D. Bernardi, et al. Phase I Trial and Pharmacokinetics of Fenretinide in Children with Neuroblastoma Clin. Cancer Res., June 1, 2003; 9(6): 2032 - 2039. [Abstract] [Full Text] [PDF]

				M. S. Tallman, C. Nabhan, J. H. Feusner, and J. M. Rowe Acute promyelocytic leukemia: evolving therapeutic strategies Blood, February 1, 2002; 99(3): 759 - 767. [Abstract] [Full Text] [PDF]

				P. C. Adamson, B. C. Widemann, G. H. Reaman, N. L. Seibel, R. F. Murphy, A. F. Gillespie, and F. M. Balis A Phase I Trial and Pharmacokinetic Study of 9-cis-Retinoic Acid (ALRT1057) in Pediatric Patients with Refractory Cancer: A Joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group Study Clin. Cancer Res., October 1, 2001; 7(10): 3034 - 3039. [Abstract] [Full Text] [PDF]

				E. J. Estlin, S. Cotterill, C. B. Pratt, A. D. J. Pearson, and M. Bernstein Phase I Trials in Pediatric Oncology: Perceptions of Pediatricians From the United Kingdom Children's Cancer Study Group and the Pediatric Oncology Group J. Clin. Oncol., May 9, 2000; 18(9): 1900 - 1905. [Abstract] [Full Text] [PDF]

				N. A. Rizvi, J. L. Marshall, W. Dahut, E. Ness, J. A. Truglia, G. Loewen, G. M. Gill, E. H. Ulm, R. Geiser, D. Jaunakais, et al. A Phase I Study of LGD1069 in Adults with Advanced Cancer Clin. Cancer Res., July 1, 1999; 5(7): 1658 - 1664. [Abstract] [Full Text] [PDF]

				P. C. Adamson All-Trans-Retinoic Acid Pharmacology and Its Impact on the Treatment of Acute Promyelocytic Leukemia Oncologist, October 1, 1996; 1(5): 305 - 314. [Abstract] [Full Text] [PDF]